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Abstract
Objective: HIBM (Hereditary Inclusion Body Myopathy) is a recessive hereditary disease characterized by adult-onset, slowly
progressive muscle weakness sparing the quadriceps. It is caused by a single missense mutation of each allele of the UDP-N-
acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) gene, a bifunctional enzyme catalyzing the first two
steps of sialic acid synthesis in mammals. However, the mechanisms and cellular pathways affected by the GNE mutation
and causing the muscle weakness could not be identified so far. Based on recent evidence in literature, we investigated a
new hypothesis, i.e. the involvement in the disease of the GM3 ganglioside, a specific glycolipid implicated in muscle cell
proliferation and differentiation.
Methods: qRT-PCR analysis of St3gal5 (GM3 synthase) gene expression and HPLC quantification of GM3 ganglioside were
conducted on muscle tissue from a mouse model of HIBM harboring the M712T mutation of GNE (Gne
M712T/M712T mouse) vs
control mice (Gne
+/+ mouse).
Results: St3gal5 mRNA levels were significantly lower in Gne
M712T/M712T mouse muscles vs Gne
+/+ mouse muscles
(64.41%610% of Gne
+/+ levels). GM3 ganglioside levels showed also a significant decrease in Gne
M712T/M712T mouse muscle
compared to Gne
+/+ mouse muscle (18.09%65.33% of Gne
+/+ levels). Although these Gne
M712T/M712T mice were described to
suffer severe glomerular proteinuria, no GM3 alterations were noted in kidneys, highlighting a tissue specific alteration of
gangliosides.
Conclusion: The M712T mutation of GNE hampers the muscle ability to synthesize normal levels of GM3. This is the first
time that a mutation of GNE can be related to the molecular pathological mechanism of HIBM.
Citation: Paccalet T, Coulombe Z, Tremblay JP (2010) Ganglioside GM3 Levels Are Altered in a Mouse Model of HIBM: GM3 as a Cellular Marker of the
Disease. PLoS ONE 5(4): e10055. doi:10.1371/journal.pone.0010055
Editor: Mark A. Tarnopolsky, McMaster University, Canada
Received January 8, 2010; Accepted March 4, 2010; Published April 7, 2010
Copyright:  2010 Paccalet et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study is supported partly by the ‘‘Ministere du Developpement economique, de l’Innovation et de l’Exportation’’ and the Neuromuscular Disease
Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Jacques P. Tremblay is president and share holder of CellGene inc. a biotechnology company.
* E-mail: Jacques-P.Tremblay@crchul.ulaval.ca
Introduction
Hereditary Inclusion Body Myopathy (HIBM, OMIM600737,
inclusion body myopathy 2, Distal Myopathy with Rimmed
Vacuoles) is a unique autosomal recessive muscle disorder,
characterized by adult-onset of muscle weakness in upper and
lower limbs. Amazingly, the quadriceps seemed to be spared until
late stages of the disease [1,2], although recent evidence suggests
that rectus femoris could be affected [3]. HIBM has been
originally described in Japanese [4] and Iranian Jews [1] but
patients are now found worldwide. HIBM muscle fibres present
typical pathology, with rimmed vacuoles and cytoplasmic and/or
nuclear filamentous inclusions. Intracellular deposits of b-amyloid
proteins, altered phosphorylation of tau or activation of the
ubiquitin proteasome or of the lysosomal systems can occasionally
be observed [1,5–7].
HIBM was mapped to chromosome 9 [8,9] and is associated
with mutations in the UDP-N-acetylglucosamine 2-epimerase/N-
acetylmannosamine kinase (Gne) gene [8]. This gene encodes a
bifunctional enzyme (hereafter designed as GNE) catalyzing the
epimerisation of UDP-N-acetylglucosamine (UDP-GlcNAc) in N-
acetylmannosamine (ManNAc) and then the phosphorylation of
ManNAc in ManNAc-6-phosphate (ManNAc-6P). These are the
first two steps of N-acetylneuraminic acid (Neu5Ac) biosynthesis
[10], the most abundant terminal sialic acid of the eukaryote
glycoconjugates. Neu5Ac is implicated in numerous cellular
functions, such as cell-cell interactions, signalling, haematopoietic
cell differentiation as well as regulation of the immune system
[11–13]. Knock-out of Gne gene causes embryonic lethality in mice
at day 8.5, highlighting the importance of sialylation [14].
GNE activities rely in two functional domains, controlling
respectively the epimerase and the kinase activities. Over 40
different mutations spreading over both domains of Gne can cause
HIBM. For example, the most prevalent mutations of Gne gene,
M712T and V572L respectively in the Middle Eastern community
and in Japanese patients, are both located in the kinase domain of
GNE, but other mutations have been identified in its epimerase
domain. All these mutations of Gne gene result in different altered
enzymatic activities [15–18], which should lead to lessened status
of cellular sialylation or at least reduced sialylation of specific
glycoproteins, such as a-dystroglycan [19,20], NCAM [21],
neprilysin [22] or aberrant activity of global systems like lysosomal
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mutations on the overall sialylation in humans remains unclear
[15,16,25]. So far, none of these works could identify the
molecular pathological mechanism of HIBM and furthermore, a
recent model of heterozygous GNE-deficient mice provided clues
that cells and organs can manage a certain amount of defects in
sialylation, at least down to an overall 25% reduction [26].
Moreover, sialic acids can be provided by exogenous sources and it
is known that cells, be it mammalian or insect cell lines, can use
circulating sialic acids to compensate their lack of this monosac-
charide [16,27,28]. The context in which experiments are
conducted is thus an important factor in the interpretation of
the results. Other studies aimed at discovering cellular processes
altered in this myopathy [29–31] have not proven anymore
successful and the molecular aspects of the disease remain obscure
yet.
Until now, the process by which mutations of GNE causes the
muscular pathology observed in HIBM remains misunderstood.
As all the characterized mutations affect differently the enzymatic
activity of GNE, but result in similar phenotypes, it is questionable
that an altered enzymatic function of GNE triggers the disease
mechanism. It is thus possible that HIBM may be a consequence
of the alteration of another yet unknown role of GNE.
Interestingly, GNE has a dynamic cellular localization, as it can
be detected in the cytosol and the nucleus simultaneously [32].
The nuclear localization, which is not required for ManNAc-6P
production, suggests alternative roles of GNE, other than the sole
pathway of sialic acid biosynthesis. Recently, several articles
underlined this hypothesis. GNE was proven to be involved in
protein-protein interactions with collapsin response mediator
protein 1 (CRMP1) and promyelocytic leukemia zinc finger
protein (PLZF)[33], the later being a transcription factor whose
knock-out alters musculoskeletal development in mice [34], and
with alpha-actinin 1 [35], which helps to anchor the myofibrillar
actin filaments.
GNE was also reported to regulate ganglioside (sialylated
glycosphingolipids) levels in HEK293T cells, especially GM3 and
GD3 [36]. In particular, cellular levels of GNE were shown to
regulate beta-galactoside alpha-2,3-sialyltransferase 5 expression
(ST3Gal5, the GM3 synthesizing enzyme). GM3 is the most
abundant ganglioside in muscle, representing almost 70% of total
ganglioside in muscle membranes [37–40]. Gangliosides, and
particularly GM3 and GD3 are involved in regulation of
numerous cellular pathways, such as migration, proliferation,
senescence and apoptosis [41–43] and ganglioside levels change
over time in muscle cells, particularly during differentiation
[44–46]. Thus, an alteration of the capacity of GNE to effectively
regulate GM3 synthesis could alter progressively the ability of
muscle cells to adapt to their environment or to cope with their
needs. To date, no investigation has been made to determine a
relation between the ganglioside synthesis regulated by GNE and
HIBM.
In 2007, two different genetically engineered mouse lines of
mutations in the GNE gene were described, harbouring either
M712T [47] or D176V [48] mutation. Both of these models aimed
at mimicking HIBM phenotype in animals, yet M712T mice
mutation lead to glomerular proteinuria, a pathology not
described in human HIBM patients. This surprising lethal renal
phenotype hindered the authors in their assessment of myopathic
features in these mice. However, the M712T strain of mice could
still help to understand specific alterations in muscles. In
particular, we investigated whether mutations in GNE could alter
the GM3 ganglioside levels of muscles and, consequently, the
insulin response of muscular cells of M712T mice.
Results
Down-regulation of ST3Gal5 expression in Gne
M712T/M712T
mouse muscle
A recent study [36] pointed out that Gne expression levels were
directly able to regulate ST3Gal5 expression levels. ST3Gal5 is the
enzyme responsible for ganglioside GM3 synthesis. So far, the
possible relationship between GM3 synthesis and HIBM was
never investigated, yet GM3 is a glycosphingolipid largely involved
in differentiation of muscle cells [44–46] and, more generally, in
numerous cellular pathways, such as migration, proliferation,
apoptosis or insulin sensitivity [42,43]. Therefore, an alteration of
its synthesis could directly lead to a vast modification of the cell
metabolism. Thus, it was of interest to test whether a single-
nucleotide mutation of Gne gene could modify ST3Gal5 expression
pattern. It was first necessary to compare the raw levels of GNE
mRNA expression between mutated (Gne
M712T/M712T) and wild-
type (Gne
+/+) mouse muscles. As shown in Figure 1a, no difference
in GNE mRNA levels could be detected in mice harboring the
mutation in regards to Gne
+/+ mice. This result is consistent with
the Gne
M712T/M712T knock-in construction, where the mutated Gne
gene remains under its natural promoter. GNE protein levels in
Gne
M712T/M712T and Gne
+/+ muscle tissue were assessed by
electrophoresis and provided us a complementary verification of
comparable GNE levels between Gne
M712T/M712T and Gne
+/+
mouse muscles (Figure 2).
An evaluation of ST3Gal5 mRNA levels was then performed in
Gne
M712T/M712T and Gne
+/+ muscle tissues by real-time RT PCR.
As shown in Figure 1b, St3gal5 gene expression decreased of
35.6%610% in Gne
M712T/M712T mice with respect to Gne
+/+
(p,0.025). This result underlines the role of GNE in the regulation
of ST3Gal5 expression.
GM3 ganglioside levels are affected in Gne
M712T/M712T
muscles, compared with Gne
+/+ muscles
Next, we measured GM3 by HPLC to ensure that changes in
ST3Gal5 mRNA levels were reflected in the actual cellular levels
of the ganglioside produced by this enzyme. As described in
Material & Methods, gangliosides were extracted by several
solvent partitions and their oligosaccharides were digested by an
endoglycoceramidase. The oligosaccharides were then derivatized
with anthranilic acid and analyzed by HPLC, as previously
demonstrated [49]. GD1b was used as internal standard, because
endogenous GD1b was undetectable in muscle tissue samples (data
not shown). Hereafter, ganglioside levels are reported as the
ratio of the peak area of GM3 to that of internal standard
GD1b (Figure 3). The GM3 levels were significantly lower in
Gne
M712T/M712T muscle than in Gne
+/+ muscle (18.09%65.33% of
Gne
+/+ levels, Student t test p=0.008751).
GM3 ganglioside levels seem unaffected in Gne
M712T/M712T
kidney, compared with Gne
+/+
Ganglioside GM3 is particularly abundant in the kidney tissues
[50]. Sialic acids are indeed important in kidneys, since their
physicochemical properties are involved in the maintenance of the
filtration barrier of glomeruli [51]. More particularly, changes in
ganglioside expression in these organs is implicated in the
pathogenesis of proteinuria [52]. More recently, it was demon-
strated that alteration of ganglioside GM3 levels in kidneys can be
related to glomerular hypertrophy and proteinuria [53].
However, our results clearly demonstrate that GM3 levels in
Gne
M712T/M712T mouse kidney are comparable with Gne
+/+ kidney
levels (figure 4). Thus, GM3 should not represent an issue in the
GM3 Changes in a Model of HIBM
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M712T on ST3Gal5 mRNA expression. A, Comparison of GNE mRNA levels between Gne
+/+ (diamond) and
Gne
M712T/M712T (square) mouse muscle determined by qRT-PCR (absolute values are expressed as the number of GNE mRNA copies/mg of total RNA). B,
ST3Gal5 mRNA levels Gne
+/+ and Gne
M712T/M712T mouse muscle (absolute values are expressed as the number of GNE mRNA copies/mg of total RNA).
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[47].
Discussion
One of the main problems when one tries to unravel the
molecular and cellular pathways of HIBM is the lack of human
muscle samples. Necessity arose to develop animal models of the
mutations in the Gne gene. Two such models were developed to
date and this study focuses on one of them, the Gne
M712T/M712T
mice.
Gne
M712T/M712T mouse mutation leads to glomerular proteinuria
[47], a pathology not described in human HIBM patients. This
surprising lethal renal phenotype hindered the authors in their
assessment of myopathic features in these mice. However, this
strain of mice could still help us to understand specific alterations
in muscle cell metabolism linked to GNE mutations. Galeano et al.
[47] previously reported that the majority of these mice did not
survive P3. In our colony, in contrast, several homozygous
Gne
M712T/M712T mice lived up to 6 months old. However the
Gne
M712T/M712T mouse phenotype remained altered in comparison
with their littermates: Gne
M712T/M712T mice were smaller than
their control littermates, had a high mortality rate before weaning
and presented renal abnormalities (data not shown). Moreover, in
our colony, no difference could be observed between GNE protein
levels of expression, here again in contrast with Galeano et al.
Our results demonstrate that in these mice, glycolipid sialyla-
tion, in particular ganglioside GM3 synthesis, is also affected. First,
the Gne
M712T/M712T mutation leads to a partial down-regulation of
ST3Gal5 mRNA synthesis. However, according to Wang
et al[36], when St3Gal5 mRNA levels were decreased to 12–
15% of normal mRNA levels, the GM3 ganglioside levels
remained 75% of normal levels. Thus, the sole effects of mutated
GNE
M712T on the mRNA levels of ST3Gal5 (i.e. a decrease of
35.6%610%) may not translate into such severe changes of GM3
in muscles (roughly 82% of diminution). However, it was reported
that in Gne
M712T/M712T mice, GNE
M712T enzyme activity showed
only 19.4%67.5% of GNE
WT activity [47]. Hence, the reduction
of GM3 may result from a synergy of a lack of sialic acid and a
blunt down-regulation of ST3Gal5.
Although beyond the scope of this article, these results
emphasize the hypothesis formulated by Wang et al. [36] that
GNE plays a role in transcription, most probably through its
association with transcription factors, as described [33]. Future
experiments with Gne
D176V mice, a mouse strain harboring another
mutation of GNE [48], could help us to determine whether
different mutations of GNE all lead to an alteration of ST3Gal5
expression.
The rough lack in GM3 ganglioside in Gne
M712T/M712T mice
could have very well explained part of the renal pathologies
observed in these animals, according to the relative abundance of
GM3 in the kidney tissues [50]. Moreover, it was previously
demonstrated that alteration of ganglioside GM3 levels in kidneys
can lead to glomerular hypertrophy and proteinuria [53].
However, we could not detect any significant difference between
GM3 levels in kidneys of GNE
M712T and GNE
WT mice. Such
results suggest that GM3 alteration related to the GNE
M712T
mutation could be specific to muscles, and would not affect other
organs. This is of primary importance as HIBM patients usually do
not develop pathologies in other tissues than muscles.
The present work emphasizes the fact that GNE is a
moonlighting enzyme, capable of multiple intracellular roles, roles
that only recent studies were able to discover [33,35,36]. The
relationship between mutations of GNE and cellular levels of
gangliosides was never explored before. Our results demonstrate
that, beyond the production of sialic acid, the synthesis of specific
molecules such as gangliosides, could be affected. Among
gangliosides, GM3 is of particular interest, due to its preponder-
ance in muscles [39]. Thus, an alteration of GM3 levels in HIBM
cells could lead to a variety of detrimental effects and modification
of cell metabolism and draw a bridge between several past
observations on HIBM cells such as impairment of myogenic
terminal differentiation (Amsili et al., personal communication) or
modification of the apoptotic signaling pathways [54] as GM3 is
precisely involved in terminal differentiation of myoblasts [44] and
the control of apoptosis [36,55].
(*, p,0.025); each data point represents a minimum of 3 replicates). Mean ST3Gal5 expression in Gne
M712T/M712T muscle was 64.41%610% of Gne
+/+
muscle, whereas no significant difference could be detected in GNE expression.
doi:10.1371/journal.pone.0010055.g001
Figure 2. Immunoblotting of muscle of Gne
+/+ and Gne
M712T/M712T
mice. Immunoblots of muscle extracts from Gne
+/+ and Gne
M712T/M712T
showed no apparent difference in GNE protein expression (upper
band, arrow, 79 kDa) in Gne
M712T/M712T mice compared with Gne
+/+
littermates.
doi:10.1371/journal.pone.0010055.g002
Figure 3. GNE
M712T muscles display changes to GM3 levels.
Gne
M712T/M712T (grey) mouse muscle experienced reduced levels of GM3
gangliosides compared with Gne
+/+ (white) muscle. HPLC data from a
minimum of five replicates are pooled for the Gne
+/+ and Gne
M712T/M712T
samples (*, p=0.008751, Student t test).
doi:10.1371/journal.pone.0010055.g003
GM3 Changes in a Model of HIBM
PLoS ONE | www.plosone.org 4 April 2010 | Volume 5 | Issue 4 | e10055In the case of muscle, lack of GM3 could not only modify the
differentiation of cells but also their insulin related metabolism.
Indeed, GM3 expression is directly related to insulin sensitivity
[56,57]. For instance, Type I Gaucher disease, which is due to
impaired breakdown of GM3 and its accumulation in macro-
phages, is also associated with peripheral insulin resistance [58].
An enhanced insulin sensitivity was also reported in mice lacking
GM3 [59]. Such modifications of GM3 expression and insulin
sensitivity will soon be investigated thoroughly in the other
available animal model of GNE mutation, developed by a
Japanese team [48,60] and in human cultured myoblasts.
If these different models all confirm that this ganglioside is
altered when GNE is mutated, GM3 levels could then be tagged as
a cellular marker of HIBM. Perhaps even more valuable, GM3
levels could be followed after genetic correction of myoblasts with
healthy Gne gene and permit us to assess the phenotype reparation
of cell. This would be the very first preliminary steps toward a cell
therapy of HIBM.
Materials and Methods
Animals
The mouse model was produced by Dr Darvish (HIBM
Research Group, Encino, USA), referred as Gne
M712T/M712T
mouse, with the most frequent mutation in the GNE gene in
Jewish HIBM patients (M712T) is available in our laboratory.
Gne
M712T/M712T and wild-type Gne
+/+ mice were in C57BL/6
background strain. Animals were used in accordance with the
animal protection committee of the CRCHUL. For all the
experiments, Gne
M712T/M712T and Gne
+/+ mice were paired for age
(4 to 6 month old, mean age 5 month old).
Primers
Primers were designed for mouse Gne and St3gal5 (beta-
galactoside alpha-2,3-sialyltransferase 5, SIAT9 or GM3 synthase)
genes following Wang et al. [36] and adapted for murine genes.
Oligonucleotide primer pairs used in this study (table 1) were
design by GeneTools software (BioTools), and their specificity was
verified by blasting in the GenBank database.
Real-Time PCR analyses
The mRNA levels of GNE and ST3Gal5 were analyzed by the
quantitative real-time polymerase chain reaction (qRT-PCR)
method. RNA was isolated from fresh Tibialis anterior tissues
(40 mg) using the RNeasy kit (Qiagen) according to the
manufacturer’s instructions from 7 Gne
+/+ and 3 Gne
M712T/M712T
mouse Tibialis anterior muscles. Five micrograms of total RNA
were converted to cDNA by incubation with 200 U SuperScript
III reverse transcriptase (Invitrogen), 50 ng random hexamers,
300 ng oligo(dT)18 in a reaction buffer containing 50 mM Tris-
HCl, pH 8.3, 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol
(DTT), 0.5 mM dNTPs and 40 U Protector RNase inhibitor
(Roche). Reaction was incubated at 25uC for 10 min, then at 50uC
for 2 h and followed by treatment with 1 mg RNase A, 37uC,
30 min. PCR purification kit (Qiagen) was used to purify cDNA.
cDNA corresponding to 20 ng of the initial total RNA was used
to perform fluorescence-based real-time PCR quantification using
the LightCycler 480 Realtime PCR apparatus (Roche Diagnos-
tics). The LightCycler 480 SYBR Green I Master (Roche
Diagnostics) was used as described by the manufacturer. The
conditions for PCR were denaturation at 95uC for 10 s, annealing
at 62uC for 10 s, and elongation at 72uC for 14 s. Reading of the
fluorescence signal was taken after heating at 76uC for 5 s, to avoid
nonspecific signal and a melting curve was performed to assess
nonspecific signal. Annealing temperature was selected based on
contamination levels and melting curve results. Prior to mRNA
quantification, RNA samples were verified for genomic DNA
contamination.
Figure 4. GNE
M712T kidney GM3 levels remain in normal range.
Gne
M712T/M712T (grey) and Gne
+/+ (white) mouse kidney gangliosides
were analyzed by HPLC. No significant difference could be noted. HPLC
data from a minimum of 3 replicates is pooled for the Gne
+/+ and
Gne
M712T/M712T samples.
doi:10.1371/journal.pone.0010055.g004
Table 1. Primers used for the analysis of GNE and ST3Gal5 expression by Real-Time PCR.
Designation Description GenBank Size (bp) Forward primer (59-39)/Reverse primer (59-39)
Gne N-acetylglucosamine 2-epimerase/N-
acetylmannosamine 6-kinase
NM_015828 251 TGCCCTTCCTATGACAAACTGCTC/CGCATCACTCGAACCATCTCCT
St3gal5 beta-galactoside alpha-2,3-
sialyltransferase 5
NM_001035228 186 GGTGTTGAGGTGGGAGGAGAG/GATGGACTAGCAGAAAGGGGTTATGAA
Atp5o ATP synthase, H+ transporting
mitochondrial F1 complex, O subunit
NM_138597 142 GCTATGCAACCGCCCTGTACTCTG/ACGGTGCGCTTGATGTAGGGATTC
Hprt1 Hypoxanthine guanine phosphoribosyl
transferase 1
NM_013556 106 CAGGACTGAAAGACTTGCTCGAGAT/CAGCAGGTCAGCAAAGAACTTATAGC
Gapdh Gyceraldehyde-3-phosphate
dehydrogrenase
NM_008084 194 GGCTGCCCAGAACATCATCCCT/ATGCCTGCTTCACCACCTTCTTG
ADNg Chromosome 3 genomic contig, strain
C57BL/6J (HSD3B1 intron)
NT_039239 209 CACCCCTTAAGAGACCCATGTT/CCCTGCAGAGACCTTAGAAAAC
doi:10.1371/journal.pone.0010055.t001
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handling, each result was corrected with three housekeeping genes,
subunit O of ATPase (Atp5o), hypoxanthin phosphoribosyltrans-
ferase (Hprt1) and glyceraldehyde-3-phosphate dehydrogenase
(Gapdh), at each assay.
Calculation of the number of copies of each mRNA was
performed according to Luu-The et al. [61]: fit point and second
derivative methods were used to determine a Cp that is used to
calculate the number of copies of initial mRNA species in the
sample using a standard.
Western blot analysis
Proteins from Tibialis anterior muscles were extracted with Total
Protein Extraction Kit (Chemicon) according to manufacturer’s
protocol. Twenty micrograms of proteins were migrated on 8%
SDS-PAGE gel and transferred on nitrocellulose membrane.
Primary antibody against Gne was provided by D. Darvish [47]
and secondary anti-chicken-HRP was from Abcam.
Glycosphingolipid extraction
Thirty milligrams of gastrocnemius muscles of 5 Gne
M712T/M712T
mice and 6 Gne
+/+ mice were extracted using a modification of the
Svennerholm and Fredman method [62] that gave maximum
recovery of gangliosides. For each of these mice, three replicates of
ganglioside extraction (followed by enzymatic digestion and
normal-phase HPLC analysis) were conducted per gastrocnemius
muscle, in order to get the most accurate measure of ganglioside
levels.
Muscle tissues were homogenized with 750 ml of Milli-Q water.
The homogenate was poured in 2.7 ml of methanol, stirred and
1.35 ml of chloroform was added. After shaking, mixture was
centrifuged at 2000 g for 15 min. Supernatant was kept aside
whereas residue was re-extracted by addition of 2.5 ml chloro-
form/methanol/Milli-Q water (4/8/3), shaking and centrifugation
at 2000 g for 15 min. The two extracts were combined and
separated in two phases by addition of 1.3 ml Milli-Q water. After
centrifugation (2000 g, 15 min), aqueous phase was removed for
further processing and organic phase was re-extracted with 750 ml
methanol and 500 ml Milli-Q water. After another centrifugation,
both aqueous phases were pooled. Chloroform traces were
eliminated under a stream of nitrogen before lyophilization of
the sample.
Purification of gangliosides was obtained by solvent partition in
di-isopropylether/1-butanol/Milli-Q water (60:40:50, v/v/v),
modified and adapted from Ladisch and Gillard [63]. Basically,
the samples were resuspended in two volumes (vol) of di-
isopropylether/1-butanol (60/40) by vortexing and sonicating.
One vol of Milli-Q water and the mixture was then stirred for
several minutes. After centrifugation (2000 g, 15 min), the
aqueous phase containing the gangliosides was carefully trans-
ferred in a new tube using a Pasteur pipet and a reextraction on
organic phase was made by addition of 0,5 vol of Milli-Q water.
Aqueous phases were combined, traces of organic solvents were
evaporated under a stream of nitrogen and the sample was
lyophilized. Extracted gangliosides were stored under nitrogen at –
80uC in chloroform/methanol (1/1).
Endoglycoceramidase digestion
Total glycosphingolipids from mouse muscle were dried under a
stream of nitrogen and then digested with 3 mU of rEGCase II
(Takara Bio Inc) in 50 ml incubation buffer (50 mM sodium
acetate, pH 5.0, 0,4% TRITON-X100), for 18 h at 37uC. One
unit is defined as the amount of enzyme that hydrolyzes 1 mmol of
ganglioside asialo-GM1, per minute at 37uC (according to the
manufacturer sheet).
Carbohydrate fluorescent labeling and analysis by
Normal Phase-HPLC (NP-HPLC)
Oligosaccharides cleaved from gangliosides were derivatized
with anthranilic acid, according to Neville et al. [49]. This
protocol consists in completing the sample digested by rEGCase II
to 60 ml with water. 160 ml of labeling solution (anthranilic acid
30 mg/ml, sodium acetate trihydrate 4% w/v, boric acid 2% w/v
and sodium cyanoborohydride 45 mg/ml, in methanol) were then
added. The mix was placed at 80uC for 60 min. The reaction was
allowed to cool to room temperature before addition of 1 ml
acetonitrile/Milli-Q water (97/3, v/v). Purification with Discovery
DPA-6S columns was conducted as follows: after pre-equilibration
of the column with 261 ml acetonitrile, samples were loaded on
the column. The column was then washed with 461m l
acetonitrile/Milli-Q water (99/1, v/v) and 0.5 ml acetonitrile/
Milli-Q water (97/3, v/v). Labeled oligosaccharides were eluted
with 260.6 ml Milli-Q water and, if needed, stored at –20uC.
Before injections, samples were lyophilized and resuspended in
Milli-Q water/acetonitrile (2/8, v/v).
NP-HPLC of purified labeled oligosaccharides was conducted
using a 4.66250 mm TSK gel amide-80 column (Tosoh
Bioscience LLC), on Alliance 2695 Waters System (Milford,
MA, USA) coupled with Model 474 Waters fluorescence detector
set at Ex_360 nm and Em_425 nm, under control of Empower
Waters software. Gradient solvents and analysis conditions were
adapted from Neville et al. (2004): solvent A (20% 100 mM
ammonium acetate, pH 3.85, in Milli-Q water and 80%
acetonitrile) and solvent B (20% 100 mM ammonium acetate,
pH 3.85, in Milli-Q water, 60% Milli-Q water, and 20%
acetonitrile). Conditions of analysis were: time t=0 min (t0),
86% solvent A (0.8 ml/min); t6, 86% solvent A (0.8 ml/min); t35,
54,7% solvent A (0.8 ml/min); t37, 5% solvent A (1 ml/min); t39,
5% solvent A (1 ml/min); t41, 86% solvent A (1 ml/min); t55,
86% solvent A (0.8 ml/min).
Standard gangliosides such as GM3 or mix of monosialylgan-
gliosides (Matreya LLC) were used to identify peaks.
Statistical tests
Fisher exact test (permutation test) was conducted to assess
significant difference between GNE and ST3Gal5 mRNA
expression. Student T test was used to compare muscle and
kidney GM3 levels of Gne
M712T/M712T and Gne
+/+ mouse samples.
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